October 01, 2024
Amgen lost an attempt to escape a potential class action claiming the pharmaceutical giant hid a $10.7 billion tax bill from investors after a New York federal court ruled there was sufficient evidence for the action to proceed.
February 28, 2024
Amgen had no obligation to disclose specific amounts of proposed adjustments to its taxes, the company told a New York federal court as it again demanded dismissal of a proposed class action alleging the company hid a $10.7 billion tax bill from investors.
November 07, 2023
Amgen Inc. asked a New York federal judge to scrap a shareholder suit claiming the biotech company hid a $10 billion tax bill from investors, arguing it wasn't required to disclose specific amounts while challenging the IRS during an audit.
July 10, 2023
A New York federal judge has appointed Robbins Geller Rudman & Dowd LLP as lead counsel in a proposed class action alleging that biotech company Amgen Inc. hid $10 billion in taxes and penalties from investors.
May 15, 2023
A New York federal court should appoint as lead plaintiff the pension fund that initially filed a securities class action against Amgen Inc. alleging it hid $10 billion in taxes and penalties from investors, the fund told the court.
March 14, 2023
Biotech company Amgen Inc. was hit with a securities class action alleging the company hid years of reports, adjustments and deficiency notices from the Internal Revenue Service, which led to artificially inflated stock prices and ultimately put it on the hook for more than $10 billion in taxes and penalties.